Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Collection of Human Serum Samples From Healthy Adults
NCT02072525Phase 4Completed
- Sponsor
- GSK
- Start
- Apr 2014
- Primary completion
- Jun 2015
- Modality
- Split/Subunit Vaccines
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of Meningococcal polysaccharide (serogroups A, C, W, and Y) tetanus toxoid conjugate vaccine, Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated), Streptococcus pneumoniae type 19f capsular polysaccharide antigen and Prevnar 13 in meningococcal infection, Tetanus, diphtheria and 2 more (3 arms), sponsored by GSK. Primary endpoint: Collection of human plasma for conversion into serum at Day 120. Started Apr 2014; status: completed.
02
Drugs
Meningococcal polysaccharide (serogroups A, C, W, and Y) tetanus toxoid conjugate vaccineBordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated)Streptococcus pneumoniae type 19f capsular polysaccharide antigenPrevnar 13
03
Conditions
meningococcal infectionTetanusdiphtheriapertussispneumococcal infection
Beyond the preview
Go deeper on NCT02072525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02072525.